SYK STRYKER CORP
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 310764 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.9%
TTM net income YoY23.1%
TTM EPS YoY23.4%
Revenue 3-yr CAGR9.8%
Net income 3-yr CAGR11.9%
Margins
Gross margin65.3%
Operating margin20.7%
Net margin13.8%
FCF margin17.4%
EBITDA margin26.8%
Returns
ROE16.0%
ROA7.7%
ROIC (approx.)11.0%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets50.4%
Debt / equity0.64x
Current ratio2.18x
Interest coverage9.27x
Cash quality & payout
Operating cash flow / net income1.50x
Accruals ratio-3.9%
Payout ratio36.8%
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $25.12B | $22.59B |
| Cost of revenue | $9.05B | $8.15B |
| Gross profit | $16.07B | $14.44B |
| R&D expense | $1.62B | $1.47B |
| SG&A expense | $8.65B | $7.68B |
| Operating income | $4.89B | $3.69B |
| Interest expense | $607.00M | $409.00M |
| Pretax income | $4.51B | $3.49B |
| Income tax | $1.27B | $499.00M |
| Net income | $3.25B | $2.99B |
| EBITDA | $6.46B | $5.12B |
| EPS (basic) | 8.49 | 7.86 |
| EPS (diluted) | 8.40 | 7.76 |
| Weighted avg. shares (diluted) | 386.50M | 385.60M |
| Balance sheet | ||
| Cash & equivalents | $4.01B | $3.65B |
| Short-term investments | $89.00M | $91.00M |
| Receivables | $4.04B | $3.99B |
| Inventory | $5.31B | $4.77B |
| Current assets | $14.76B | $14.85B |
| PP&E, net | $3.88B | $3.45B |
| Goodwill | $19.29B | $15.86B |
| Intangibles | $5.68B | $4.39B |
| Total assets | $47.84B | $42.97B |
| Current liabilities | $7.79B | $7.62B |
| Short-term debt | $1.00B | $1.41B |
| Long-term debt | $14.86B | $12.19B |
| Total debt | $15.86B | $13.60B |
| Total liabilities | $25.42B | $22.34B |
| Shareholders' equity | $22.42B | $20.63B |
| Net debt | $11.85B | $9.95B |
| Cash flow statement | ||
| Operating cash flow | $5.04B | $4.24B |
| Capital expenditure | $761.00M | $755.00M |
| Free cash flow | $4.28B | $3.49B |
| Investing cash flow | -$4.87B | -$3.00B |
| Financing cash flow | $113.00M | -$525.00M |
| Depreciation & amortization | $1.57B | $1.43B |
| Stock-based compensation | $243.00M | $229.00M |
| Dividends paid | $1.28B | $1.22B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.